Last Updated: October 16th, 2025
In the evolving healthcare landscape, economic models must adapt to reflect real-world evidence and support effective value communication. Our Market Access team updates and adapts economic models to ensure they align with current data and address stakeholders’ needs.
What Is Economic Model Update and Adaptation?
Economic model update and adaptation involve revising existing models to incorporate new real-world evidence (RWE), ensuring they remain relevant and accurate for decision-making. This process includes:
- Model Design: Developing deterministic decision-tree models from specific healthcare payer perspectives, considering relevant time horizons.
- Model Validation: Validating models externally with healthcare payers and internally using standard model checklists to ensure accuracy and reliability.
- Data Integration: Incorporating observational research into models, allowing users to switch between different evidence bases that informed the analysis.
How Our Technology Delivers Results
Our specialists combine strategic insight and clinical knowledge to build models that drive meaningful decisions.
Model Architecture: Developed a decision-tree framework tailored to the specific healthcare system, capturing a two-year treatment horizon.
Robust Validation: Cross-checked outputs with payer input and internal quality protocols to ensure reliability and confidence in results.
Integrating Real-World Data: Added observational evidence, giving users the ability to explore multiple datasets and perspectives when evaluating outcomes.
How Our Practical Agility Keeps Teams Ahead
We deliver solutions efficiently by combining a lean structure with rapid collaboration, keeping projects responsive to evolving needs.
Interactive Tools: Created intuitive interfaces with layered explanations, guided navigation, and embedded patient journey context for easy adoption.
Evidence-Driven Messaging: Translated model outputs into clear value narratives and actionable objection-handling strategies for stakeholders.
Comprehensive Documentation: Produced user manuals and technical reports that clarify model assumptions, calculations, and practical applications.
Customer Testimonies
Why This Matters for Value Communication
By continuously updating and adapting economic models, our market access team ensures that stakeholders have access to the most current and relevant information, supporting effective value communication and informed decision-making in the healthcare sector.
Key Takeaways for Maximizing Model Impact
Foster cross-team collaboration early to ensure assumptions and priorities align from the start.
Prioritize transparency in your modeling process to build credibility with payers and stakeholders.
Adopt an iterative approach, treating models as dynamic tools that evolve with new evidence.
Customize insights and narratives for different payer audiences and geographic markets.
Leverage model findings to proactively identify and fill evidence gaps through targeted research.
Is your economic model up to date?
Meet our Modeling Experts
Dawn Lee
Strategic Council member
Dawn is a highly experienced health economic modeler with over 50 submissions to the UK Health Technology Assessment. She has worked across more than 30 countries globally and is a member of NICE’s interventional procedures advisory committee and the R for HTA group. Dawn is particularly focused on oncology modeling, immune-oncology, and flexible survival modeling. She also provides training on NICE processes and regularly represents clients at Committee meetings.
Holly Guy
Executive Director
She has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has over 30 successful HTA submissions, including those to NICE, SMC, and AWMSG in the UK, as well as in several European countries. She has attended and represented pharma companies at NICE and AWMSG appraisal committee meetings. She led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Vicki Laskier
Director
Vicki specializes in the strategy and implementation of HEOR solutions. With extensive experience in developing HTA dossiers, systematic literature reviews, and economic models, she has contributed to over 19 HTA submissions across NICE, SMC, and NCPE. Vicki has also represented companies at HTA meetings, leading the development of tools that support both payer and internal needs. Her work in statistical analysis, including Bayesian methods and network meta-regressions, has been widely used in healthcare decision-making.
FAQs on Global Price Targeting
- What is economic model update and adaptation?
It involves revising existing models to incorporate new real-world evidence, ensuring they remain relevant and accurate for decision-making. - How does Fiecon update economic models?
Fiecon, a Herspiegel company, updates models by integrating observational research, validating them with healthcare payers, and designing user-friendly tools to support value messaging. - Why are regular model updates important?
Regular updates ensure that economic models reflect the latest evidence, support effective value communication, and facilitate informed decision-making. - Who benefits from updated economic models?
Stakeholders across the healthcare sector, including payers, providers, and pharmaceutical companies, benefit from updated models that provide accurate and actionable insights.